The German DEAL Consortium and Springer Nature have announced the signing of a new Open Access (OA) agreement that will boost international reach and impact for Germany-based researchers and provide academic institutions in Germany with open-access publication options and reading access to world-leading content.
Under the agreement, researchers from participating institutions will continue to be able to publish OA in Springer Nature’s OA and hybrid Springer, Palgrave, and Adis journals as well as in its fully OA Nature titles and BioMedCentral journals; participating institutions will continue to benefit from attractive terms when their researchers publish Open Access (OA); and researchers at participating institutions retain reading access to articles across the Springer, Palgrave and Adis portfolios.
Signed on November 24 by Springer Nature and MPDL Services gGmbH as the DEAL operating Entity, the agreement runs from 2024 through 2028. It does not include the hybrid Nature branded journals. The parties intend to continue discussion on these titles in 2024 following the end of the existing Framework Agreement with MPDL.
The preceding agreement between DEAL and Springer Nature from 2020 has played a significant role in advancing the transition to Open Access in Germany without driving up costs. Since then, the number of published OA articles in Springer Nature journals has increased to more than 50.000. It also significantly improved the accessibility of Springer Nature journal content, as article usage within Germany rose by more than 50 percent across the portfolio over the contracted period.
Click here to read the original press release.
